Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Adenocarcinoma of the gallbladder and extrahepatic biliary tract is a rare epithelial carcinoma, arising either in the gallbladder itself or from the epithelium lining the extrahepatic biliary tree, cystic duct and/or peribiliary gland, characterized by nonspecific symptoms, such as abdominal pain, jaundice and vomiting and sometimes mimicking benign biliary diseases. Chronic biliary epithelial inflammation (e.g. primary sclerosing cholangitis, cholelithiasis, choledocholithiasis, liver fluke infestation) is a major risk factor.
Biomarker and diagnostic research for adenocarcinoma of gallbladder and extrahepatic biliary tract has been reported in the published literature.
No clinical trials have been registered for adenocarcinoma of gallbladder and extrahepatic biliary tract.
37 publications have been identified in PubMed for adenocarcinoma of gallbladder and extrahepatic biliary tract. Research spans Review / Meta-Analysis (30%), Epidemiology / Natural History (24%), and Case Report / Case Series (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 11 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 2:24 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about adenocarcinoma of gallbladder and extrahepatic biliary tract
Disease patterns and progression |
9 |
24% |
Patient case studies | 5 | 14% |
Laboratory research | 5 | 14% |
Testing and diagnosis research | 3 | 8% |
Clinical study results | 3 | 8% |
New treatment approaches | 1 | 3% |
Liu G (2026). [PMID: 42084801](https://pubmed.ncbi.nlm.nih.gov/42084801/). *Antonie Van Leeuwenhoek*. [Basic Science / Preclinical]
Barsch M (2026). [PMID: 41535645](https://pubmed.ncbi.nlm.nih.gov/41535645/). *J Gastrointest Cancer*. [Review / Meta-Analysis]
Wymer G (2026). [PMID: 42039855](https://pubmed.ncbi.nlm.nih.gov/42039855/). *Case Rep Pathol*. [Case Report / Case Series]
Utsumi M (2025). [PMID: 40026841](https://pubmed.ncbi.nlm.nih.gov/40026841/). *Surg Case Rep*. [Case Report / Case Series]
Kashima H (2025). [PMID: 40232607](https://pubmed.ncbi.nlm.nih.gov/40232607/). *Clin J Gastroenterol*. [Case Report / Case Series]
Jo H (2025). [PMID: 40155012](https://pubmed.ncbi.nlm.nih.gov/40155012/). *Anticancer Res*. [Diagnostic / Biomarker]
Nie J (2025). [PMID: 39570809](https://pubmed.ncbi.nlm.nih.gov/39570809/). *Cancer Res*. [Basic Science / Preclinical]
Angerilli V (2025). [PMID: 40215597](https://pubmed.ncbi.nlm.nih.gov/40215597/). *ESMO Open*. [Gene Therapy / Novel Therapeutics]
Ruffat A (2025). [PMID: 40220611](https://pubmed.ncbi.nlm.nih.gov/40220611/). *Eur J Surg Oncol*. [Case Report / Case Series]
Khursheed AA (2025). [PMID: 41243906](https://pubmed.ncbi.nlm.nih.gov/41243906/). *J Pak Med Assoc*. [Basic Science / Preclinical]